Cardiovascular disease gets personal
- 19 August 2009
- journal article
- Published by Springer Science and Business Media LLC in Nature
- Vol. 460 (7258), 940-941
- https://doi.org/10.1038/460940a
Abstract
No abstract availableThis publication has 13 references indexed in Scilit:
- Evaluation of risk prediction updates from commercial genome-wide scansGenetics in Medicine, 2009
- Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort studyThe Lancet, 2009
- Cytochrome P-450 Polymorphisms and Response to ClopidogrelThe New England Journal of Medicine, 2009
- Genetic Determinants of Response to Clopidogrel and Cardiovascular EventsThe New England Journal of Medicine, 2009
- Cardiovascular Disease Risk Prediction With and Without Knowledge of Genetic Variation at Chromosome 9p21.3Annals of Internal Medicine, 2009
- Cost-Effectiveness of Using Pharmacogenetic Information in Warfarin Dosing for Patients With Nonvalvular Atrial FibrillationAnnals of Internal Medicine, 2009
- Clinical Risk Factors, DNA Variants, and the Development of Type 2 DiabetesThe New England Journal of Medicine, 2008
- Assessing the Combined Impact of 18 Common Genetic Variants of Modest Effect Sizes on Type 2 Diabetes RiskDiabetes, 2008
- Predicting Type 2 Diabetes Based on Polymorphisms From Genome-Wide Association StudiesDiabetes, 2008
- Randomized Trial of Genotype-Guided Versus Standard Warfarin Dosing in Patients Initiating Oral AnticoagulationCirculation, 2007